Suven Seeks Permission for Trials of New Drug

by Jayashree on  July 13, 2007 at 5:00 PM Drug News
RSS Email Print This Page Comment bookmark
Font : A-A+

Suven Seeks Permission for Trials of New Drug
Hyderabad, July 12 (IANS) Suven Life Sciences has submitted an application with the Drug Controller General of India for permission to undertake phase-1 clinical trials of its new drug Suvn-502 for treatment of cognitive disorders such as Alzheimer's and schizophrenia.

'Treatment for Alzheimer's disease and Schizophrenia is an unmet medical need and Suven's primary focus is to discover drugs that address significant unmet medical needs,' said a statement by the firm.

Suven is a Hyderabad-based life sciences company, which is involved in contract research and manufacturing services, drug discovery and development support services and collaborative research partner with global pharma majors.

Suven's research focuses on developing treatments for Central Nervous System (CNS) disorders through novel mechanisms using small-molecule medicinal chemistry approaches.

Source: IANS
JAY/M

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Drug Toxicity Clinical Trials - Different Phases of the trial Signature Drug Toxicity 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive

Loading...